a developer of neuro-robotic technology
Industry MedicalNursingServices
This is a Bearish indicator signaling MYO's price could decline from here. Traders may explore shorting the stock or put options. A.I. dvisor identified 42 similar cases where MYO's MACD histogram became negative, and of them led to successful outcomes. Odds of Success:
MYO saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 16, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 41 instances where the indicator turned negative. In 40 of the 41 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MYO as a result. In 65 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
MYO moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MYO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MYO entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +17.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where MYO advanced for three days, in 196 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
MYO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.221) is normal, around the industry mean (4.142). P/E Ratio (-3.559) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.262) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. MYO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MYO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Myomo, Inc. is a wearable medical robotics company headquartered in Burlington, Massachusetts, listed on the NYSE American exchange. The company develops and markets the MyoPro product line, a powered upper-limb orthosis — a custom-fabricated arm brace — that reads a patient's own electromyography (EMG) signals through non-invasive sensors and uses lightweight motors to restore movement to weakened or paralyzed arms.
MyoPro is registered with the U.S. Food and Drug Administration as a Class II medical device and is the only marketed device in the U.S. that senses a patient's own EMG signals to help restore the ability to perform daily activities such as feeding, carrying objects, and household tasks. It serves people affected by stroke, brachial plexus injury, spinal cord or traumatic brain injury, and other neuromuscular conditions.
Myomo generates revenue by selling directly to patients while billing insurers, through orthotics and prosthetics (O&P) providers, to the Veterans Health Administration, and internationally. Investors follow the stock because of its expanding reimbursement coverage — covered lives have grown from roughly 9 million to about 158 million since Medicare coverage began in April 2024 — and its stated path toward operating leverage and profitability.
Over the trailing 30 days, MYO has fallen about 16.6%, from a closing price near $1.45 to roughly $1.21. The decline was not a single sharp event but a steady drift lower as earlier gains were given back.
The picture over the last quarter is more nuanced. Shares entered the period near $1.31 in early August, surged to a multi-month peak near $1.86 in mid-August following second-quarter results, and then faded. Measured from the early-August level of about $1.31, the stock is down roughly 8% over the past three months — a decline that largely reflects the reversal of a post-earnings spike rather than a sustained deterioration in the underlying business.
The recent 30-day decline did not stem from a single earnings report or major negative catalyst. Instead, it reflects a gradual unwind of the August rally, profit-taking after a sharp run, and the elevated volatility typical of a sub-$100 million market-capitalization stock with relatively thin liquidity.
During the period, Myomo named Mary-Katherine McClure as its Chief Commercial Officer, a leadership addition rather than a financial event. Third-party risk-monitoring services also flagged heightened share-price volatility and modest insider selling over the prior months, factors that can weigh on short-term sentiment for micro-cap equities. With third-quarter results scheduled for early-to-mid November, traders also appeared to position cautiously ahead of the company's next earnings update and any revision to full-year guidance.
The quarter's defining event was Myomo's second-quarter report. Revenue rose 21% year over year to about $11.7 million, exceeding estimates, while gross margin expanded to 72.1% and adjusted EBITDA improved materially. Management raised full-year 2026 revenue guidance to a range of $45 million to $47 million, and the stock rallied sharply in response, climbing from roughly $1.06 in early August to a peak near $1.86 by mid-August.
As the quarter progressed, however, shares gave back most of those gains. Investors weighed the company's continued net losses against a longer-term profitability timeline, while macro pressures on Medicare Advantage plans and the inherent lumpiness of a multi-quarter reimbursement cycle tempered enthusiasm. The result was a multi-month fade that left the stock below its pre-rally level by early November.
Tickeron's Trending AI Robots page curates a selection of automated trading bots from a platform that offers hundreds of AI-driven robots trading thousands of tickers. Only the top-performing and most relevant bots appear in this section, making it a focused starting point for traders evaluating systematic strategies. The bots vary widely in approach, timeframe, and performance metrics, so users can compare different methodologies before choosing one that aligns with their objectives. For those interested in complementing fundamental research on stocks like MYO with algorithmic signals, the page provides a practical overview of currently favored AI strategies.
Several factors are likely to shape Myomo's outlook. Third-quarter earnings and any update to full-year revenue guidance are the most immediate focal points. Investors will also watch the company's reimbursement progress, including additional state contracts under its Elevance Health arrangement and further expansion of covered lives, as well as the rollout of the MyoPro through Ottobock Care clinics.
Product and clinical milestones matter as well. Development of the next-generation MyoPro 3 platform and six-month data from the University of Utah randomized controlled trial could influence payer coverage and long-term demand. Internationally, Myomo's German expansion and a planned hand-only device address a larger addressable market. Finally, the company's ability to demonstrate operating leverage, narrow losses, and reduce cash burn remains central to how the stock is valued.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.